Keith DiPetrillo
Overview
Explore the profile of Keith DiPetrillo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
892
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alb M, Reiche K, Rade M, Sewald K, Loskill P, Cipriano M, et al.
J Immunotoxicol
. 2024 Dec;
21(sup1):S13-S28.
PMID: 39655500
The success of cellular immunotherapies such as chimeric antigen receptor (CAR) T cell therapy has led to their implementation as a revolutionary treatment option for cancer patients. However, the safe...
2.
Koch A, Schiering N, Melkko S, Ewert S, Salter J, Zhang Y, et al.
Blood
. 2019 Jan;
133(13):1507-1516.
PMID: 30692123
A large unmet medical need exists for safer antithrombotic drugs because all currently approved anticoagulant agents interfere with hemostasis, leading to an increased risk of bleeding. Genetic and pharmacologic evidence...
3.
Zhang J, Leifer F, Rose S, Chun D, Thaisz J, Herr T, et al.
Front Microbiol
. 2018 Jun;
9:915.
PMID: 29867826
Non-tuberculous mycobacteria (NTM) cause pulmonary infections in patients with structural lung damage, impaired immunity, or other risk factors. Delivering antibiotics to the sites of these infections is a major hurdle...
4.
Corboz M, Zhang J, LaSala D, DiPetrillo K, Li Z, Malinin V, et al.
Pulm Pharmacol Ther
. 2018 Feb;
49:95-103.
PMID: 29408757
Idiopathic pulmonary fibrosis is a progressive and lethal disease and while there are now two approved drugs (Esbriet and Ofev) additional effective treatments are still needed. Recently, prostacyclin analogs such...
5.
Yamada K, Levell J, Yoon T, Kohls D, Yowe D, Rigel D, et al.
J Med Chem
. 2017 Aug;
60(16):7099-7107.
PMID: 28771350
The observed structure-activity relationship of three distinct ATP noncompetitive With-No-Lysine (WNK) kinase inhibitor series, together with a crystal structure of a previously disclosed allosteric inhibitor bound to WNK1, led to...
6.
Yamada K, Park H, Rigel D, DiPetrillo K, Whalen E, Anisowicz A, et al.
Nat Chem Biol
. 2016 Sep;
12(11):896-898.
PMID: 27595330
The With-No-Lysine (K) (WNK) kinases play a critical role in blood pressure regulation and body fluid and electrolyte homeostasis. Herein, we introduce the first orally bioavailable pan-WNK-kinase inhibitor, WNK463, that...
7.
Thaisz J, Tsaih S, Feng M, Philip V, Zhang Y, Yanas L, et al.
Am J Physiol Renal Physiol
. 2012 Aug;
303(7):F972-81.
PMID: 22859403
Albuminuria is an important marker of nephropathy that increases the risk of progressive renal and chronic cardiovascular diseases. The genetic basis of kidney disease is well-established in humans and rodent...
8.
Zhang W, Korstanje R, Thaisz J, Staedtler F, Harttman N, Xu L, et al.
G3 (Bethesda)
. 2012 Mar;
2(2):167-74.
PMID: 22384395
Recent developments in high-density genotyping and statistical analysis methods that have enabled genome-wide association studies in humans can also be applied to outbred mouse populations. Increased recombination in outbred populations...
9.
10.
Xu L, Zhang Y, Cohen S, DiPetrillo K
Am J Hypertens
. 2010 Mar;
23(7):732-6.
PMID: 20300069
Background: Brain-derived neurotrophic factor (BDNF) regulates food intake and body weight, but is not useful as a therapeutic because of its short half-life. Chronic activation of its receptor, tyrosine kinase...